Article Text

Download PDFPDF
Comparison of Perioperative Outcomes and Complication Rates Between Conventional Versus Robotic-Assisted Laparoscopy in the Evaluation and Management of Early, Advanced, and Recurrent Stage Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
  1. Farr Reza Nezhat, MD*,
  2. Tamara Natasha Finger, MD*,
  3. Patrick Vetere, MD,
  4. Amir Reza Radjabi, MD,
  5. Mario Vega, MD*,
  6. Lauren Averbuch, MD,
  7. Susan Khalil, MD*,
  8. Sadiman Kiykac Altinbas, MD§ and
  9. Daniel Lax
  1. *St Luke’s Roosevelt Hospital, Columbia University, New York;
  2. Winthrop University Hospital, Mineola; and
  3. New York Downtown Hospital, Weill Cornell Medical College, New York, NY;
  4. §Etlik Zubeyde Hanim Women’s Health Training and Research Hospital, Ankara, Turkey; and
  5. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  1. Address correspondence and reprint requests to Farr Reza Nezhat, MD, Department of OB/GYN, St Luke’s Roosevelt Hospital, Columbia University, Roosevelt Hospital, 10th Floor, 1000 10th Ave, New York, NY 10019. E-mail: fnezhat{at}chpnet.org.

Abstract

Objective The objective of this study was to examine perioperative outcomes, including complication rates, of conventional laparoscopy (CL) versus robotic-assisted laparoscopy (RALS) in the evaluation and management of early, advanced, and recurrent ovarian, fallopian tube, and peritoneal cancer.

Methods This is a retrospective analysis of a prospectively maintained database of surgery performed from July 2008 to December 2012. Sixty-three women had 83 surgeries performed; 22 surgeries for early-stage disease (International Federation of Gynecology and Obstetrics stage I) and 61 for advanced and/or recurrent disease.

Results Of the 22 for early stage, 10 were CL, 9 were RALS, and 3 were laparoscopy converted to laparotomy (LP). There was no significant difference between CL and RALS in estimated blood loss (EBL, P = 0.27) or length of stay (LOS, P = 0.43); however, both had significantly less EBL (P = 0.03 and 0.03, respectively) and LOS (P = 0.03 and 0.03) than LP. There was no difference in OR time among the groups (P = 0.79). One patient (33%) had an intraoperative complication in LP. One patient (10%) had a postoperative complication in CL, 2 (22%) in RALS, and 1 (33%) in LP, with no significant difference (P = 0.61).

Among the 42 patients with advanced/recurrent disease, 61 surgeries were performed: 14 diagnostic procedures and 47 cytoreductive surgeries. Of the 47, there was no difference in operating room time (P = 0.10). There was no difference in EBL or LOS between CL and RALS (P = 0.82, P = 0.87); however, both were less in CL (P < 0.001 and P = 0.02) and RALS (P = 0.01 and P = 0.02) compared with LP. There were 5 (63%) intraoperative transfusions in LP and none in CL or RALS. When including all surgeries for advanced/recurrent disease, there was 1 intraoperative complication (12%) in LP. There was no difference in postoperative complications between groups (P = 0.89); 8 patients (19%) had postoperative complications in CL, 2 (18%) in RALS, and 2 (25%) in LP. Overall, there were no grade 4 or 5 complications and no perioperative or intraoperative deaths.

Conclusions In our experience, perioperative outcomes are comparable between CL and RALS in both early and advanced/recurrent disease and not inferior to laparotomy, making CL and RALS an acceptable approach in selected patients.

  • Laparoscopy
  • Robotic-assisted laparoscopy
  • Ovarian cancer
  • Fallopian tube cancer
  • Peritoneal cancer
  • Early stage
  • Advanced stage
  • Recurrent stage
  • Perioperative outcomes
  • Complication rates

Statistics from Altmetric.com

Footnotes

  • This study has no sources of support.

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.